Stronger pharma merger control depends on CCI performance
IFLR is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Stronger pharma merger control depends on CCI performance

The Government of India wants to encourage foreign direct investment in the country’s pharmaceutical industry, but not to the detriment of domestic players. And while it sees the Competition Commission of India playing a key role in the control of prices, not everyone believes this will be sufficient

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
Gift this article